Opening book details…
Can I read Romiplostim in Patients with Refractory Aplastic Anaemia Previously Treated with Immunosuppressive Therapy: a Dose-finding and Long-term Treatment Phase 2 Trial on EtoBox?
Romiplostim in Patients with Refractory Aplastic Anaemia Previously Treated with Immunosuppressive Therapy: a Dose-finding and Long-term Treatment Phase 2 Trial by Jong Wook Lee; Sung-Eun Lee; Chul Won Jung; Silvia Park; Hiroyuki Keta; Soo Kyeong Park; Jin-A Kim; Il-Hoan Oh; Jun Ho Jang is a Medicine article available to read on EtoBox.
What is Romiplostim in Patients with Refractory Aplastic Anaemia Previously Treated with Immunosuppressive Therapy: a Dose-finding and Long-term Treatment Phase 2 Trial about?
## Background: Aplastic anaemia is a rare, life-threatening condition, characterised by pancytopenia with hypocellular bone marrow. haematopoietic stem cells and most progenitor cells express thrombopoietin receptor (c-mpl). romiplostim is a peptibody with c-mpl agonist activity that stimulates endogenous thrombopoietin production and leads to promoting the proliferation and differentiation of megakaryocytes in the bone marrow. in this phase 2 trial we aimed to assess the activity and safety of romiplostim in patients with aplastic anaemia who were previously treated with immunosuppressive therapy. ## Methods: We did an open-label, phase 2 study including a randomised, parallel, dose-finding part followed by an extension part to evaluate long-term treatment at two clinical centres in seoul, south korea. eligible patients were aged 19 years or older, and had aplastic anaemia confirmed by bone marrow and cytogenetic studies and thrombocytopenia (platelet count ≤30 × 10/l), an eastern cooperative oncology group performance status score of 2 or lower, and were previously treated with immunosuppressive therapy, including at least one course of antithymocyte globulin plus cyclosporin. in
Who reads Romiplostim in Patients with Refractory Aplastic Anaemia Previously Treated with Immunosuppressive Therapy: a Dose-finding and Long-term Treatment Phase 2 Trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Jong Wook Lee; Sung-Eun Lee; Chul Won Jung; Silvia Park; Hiroyuki Keta; Soo Kyeong Park; Jin-A Kim; Il-Hoan Oh; Jun Ho Jang
- Published
- 2019
- Language
- EN
- Field
- Medicine (Health Sciences)